Your session is about to expire
← Back to Search
Risankizumab for Pediatric Psoriasis (OptIMMize-2 Trial)
OptIMMize-2 Trial Summary
This trial will evaluate the safety and efficacy of risankizumab in pediatric participants with moderate to severe plaque psoriasis.
OptIMMize-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 244 Patients • NCT04102007OptIMMize-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
Frequently Asked Questions
If a patient is below the age of 40, can they be still be included in this experiment?
"This study includes children that are at least 6 years old but no older than 17."
How many different facilities are coordinating this trial?
"SCDI /ID# 248828 in Reno, Apex Dermatology & Skin Surgery Center /ID# 248830 in Mayfield Heights, and Univ Hosp Cleveland /ID# 248825 in Cleveland are a few of the 18 locations that are taking part in this trial."
Could I possibly take part in this research project?
"As this is a children's study, only young patients aged 6 to 17 who have psoriasis are applicable. In total, the research team needs to recruit 132 participants."
Are patients being enrolled in this research project at present?
"Unfortunately, this specific trial is not currently looking for patients to enroll. Although the 208 other trials might be of interest, they are not related. This particular study was originally posted on 7/24/2021 and was last updated on 11/9/2022 according to clinicaltrials.gov"
What are common indications for Risankizumab?
"Risankizumab is not just limited to treating dental plaque, but can also be used for patients with psoriasis, skin disinfection therapy, and psoriatic arthritis."
What is the experimental history of Risankizumab?
"As of now, there are 29 clinical trials underway for Risankizumab. Out of those, 14 are in their third and final phase. Although the majority of these studies originate from Gdansk, Pomorskie, there are 3206 total research sites conducting these experiments."
How many people are currently signed up for this research project?
"As of right now, this clinical trial is not searching for any more participants. According to the most recent update on November 9th, 2022, this study was first posted on July 24th, 2021. There are a total of 179 trials involving psoriasis patients and 29 trials concerning Risankizumab that are actively recruiting individuals as we speak."
Are there any serious side effects associated with Risankizumab?
"Phase 3 trials have collected data supporting efficacy and safety, so Risankizumab was given a score of 3 for safety."
Share this study with friends
Copy Link
Messenger